Founder and CEO Marshall Fordyce talks about the data that supported the application and describes how atacicept’s novel mechanism holds the potential to transform the treatment of the autoimmune disease. He says the company is getting ready to launch, with a PDUFA date set for July.

Marshall Fordyce discusses the results for this fusion protein that binds to both BAFF and APRIL. The company says it saw eGFR...

Marshall Fordyce describes the rationale of targeting both BAFF and APRIL as a B-cell modulator for IgAN.